detalimogene voraplasmid
AssetAlso called detalimogene, EG-70
Non-viral gene delivery promotes local interferon alpha-2b expression to induce antitumor immune activity in the bladder.
- Stage
- Preclinical
- Modality
- Gene therapy
- Target
- Not known
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Bcg-unresponsive high-risk non-muscle-invasive bladder cancer
Preclinical, businesswire.com, Oct 13, 2026
In the full profile
- Owner and partners1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.